Spyre Therapeutics Inc (SYRE)

NASDAQ

Currency in USD

14.625

-0.305(-2.04%)

Real-time Data·15:12:55

Fair Value

Unlock Value

Day's Range

14.132

14.960

52 wk Range

10.910

40.490

SYRE Income Statement

Explore the detailed Spyre Therapeutics Inc income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Spyre Therapeutics Inc's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Total Revenues

aa.aa

18.74

2.33

0.89

Total Revenues Growth

aa.aa

-87.57%

-61.96%

Cost Of Revenues

aa.aa

59.64

57.07

58.58

84.05

162.79

Gross Profit

aa.aa

-59.64

-38.33

-56.25

-83.16

-162.79

Gross Profit Growth

aa.aa

+7.68%

+35.73%

-46.75%

-47.84%

-95.76%

Gross Profit Margin %

aa.aa

-204.55%

-2,415.2%

-9,385.89%

Other Operating Expenses, Total

aa.aa

21.84

27.32

28.53

34.45

45.78

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+38.83%	+25.07%	+4.44%	+20.76%	+32.87%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	21.84	27.32	28.53	34.45	45.78
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-81.48

-65.65

-84.78

-117.61

-208.57

Operating Income Growth

aa.aa

-1.43%

+19.43%

-29.14%

-38.72%

-77.33%

EBIT Margin %

aa.aa

-350.33%

-3,640.23%

-13,274.49%

Net Interest Expenses

aa.aa

0.59

0.11

0.84

6.15

21.31

Net Interest Expenses Growth

aa.aa

-72.33%

-81.28%

+654.05%

+634.41%

+246.71%

Interest Expense, Total

aa.aa

Interest And Investment Income

aa.aa

0.59

0.11

0.84

6.15

21.31

Other Non Operating Expenses, Total

aa.aa

-0.01

-0.12

-0.01

-102.66

-20.71

EBT, Excl. Unusual Items

aa.aa

-80.89

-65.66

-83.95

-214.13

-207.97

Gain (Loss) On Sale Of Assets

aa.aa

16.45

Other Unusual Items, Total

aa.aa

-130.19

EBT, Incl. Unusual Items

aa.aa

-80.89

-65.66

-83.95

-338.82

-207.97

EBT, Incl. Unusual Items Growth

aa.aa

-3.37%

+18.83%

-27.86%

-303.59%

+38.62%

EBT, Incl. Unusual Items Margin

aa.aa

-350.39%

-3,604.59%

-38,241.08%

Income Tax Expense

aa.aa

0.14

-0.14

-0.03

0.05

Net Income to Company

aa.aa

-80.89

-65.8

-83.82

-338.79

-208.02

Minority Interest

aa.aa

Net Income

aa.aa

-80.89

-65.8

-83.82

-338.79

-208.02

Net Income Growth

aa.aa

-3.37%

+18.66%

-27.38%

-304.21%

+38.6%

Net Income Margin %

aa.aa

-351.14%

-3,598.75%

-38,238.15%

Preferred Dividend and Other Adjustments

aa.aa

-243.91

-58.46

Net Income to Common Excl. Extra Items

aa.aa

-80.89

-65.8

-83.82

-94.88

-149.56

Basic EPS - Continuing Operations

aa.aa

-37.89

-25.02

-24.86

-13.76

-3.18

Basic EPS - Continuing Operations Growth

aa.aa

+38.12%

+33.97%

+0.64%

+44.67%

+76.88%

Diluted EPS - Continuing Operations

aa.aa

-37.89

-25.02

-24.86

-13.76

-3.18

Diluted EPS - Continuing Operations Growth

aa.aa

+38.12%

+33.97%

+0.64%

+44.67%

+76.88%

Basic Weighted Average Shares Outstanding

aa.aa

2.13

2.63

3.37

6.9

47.03

Diluted Weighted Average Shares Outstanding

aa.aa

2.13

2.63

3.37

6.9

47.03

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-80.49

-64.07

-83.21

-116.87

-207.82

EBITDA Growth

aa.aa

-0.71%

+20.39%

-29.87%

-40.44%

-77.83%

EBITDA Margin %

aa.aa

-341.92%

-3,572.95%

-13,190.52%

EBIT

aa.aa

-81.48

-65.65

-84.78

-117.61

-208.57

* In Millions of USD (except for per share items)

US 30

42,239.80

-170.3

-0.40%

US 500

5,902.20

+58.0

+0.99%

Dow Jones

42,243.68

-166.42

-0.39%

S&P 500

5,901.32

+57.15

+0.98%

Nasdaq

19,051.66

+343.32

+1.84%

S&P 500 VIX

17.82

-0.58

-3.15%

Dollar Index

100.812

-0.787

-0.77%

Market Movers

Name	Last	Chg. %	Vol.
NVDA	130.28	+5.92%	273.74M
PLTR	129.55	+9.36%	126.15M
TSLA	335.88	+5.50%	114.10M
UNH	311.95	-17.64%	48.09M
AMZN	212.39	+1.80%	41.26M
COIN	258.40	+24.70%	30.50M
META	658.69	+3.01%	14.49M

Trending Stocks

Name	Last	Chg. %	Vol.
NVDA	130.28	+5.92%	273.74M
TSLA	335.88	+5.50%	114.10M
UNH	311.95	-17.64%	48.09M
PLTR	129.55	+9.36%	126.15M
AMZN	212.39	+1.80%	41.26M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaa A	302.62	+40.69%	425.76
Aaaaaaaaaaaaaaa Aa	34.88	+40.49%	49.00
A Aaaaaaaaaaa Aaaaa	94.88	+30.58%	123.89
Aa Aaaa Aaa	142.84	+26.02%	180.01
A Aaaaaa A Aaaa Aaaa	110.17	+21.59%	133.96
Aaaaaaaaa	29.25	+21.44%	35.52
Aaaaaaaaaaaa	27.71	+21.22%	33.59

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaa A	302.62	+40.69%	425.76
Aaaaaaaaaaaaaaa Aa	34.88	+40.49%	49.00
A Aaaaaaaaaaa Aaaaa	94.88	+30.58%	123.89
Aa Aaaa Aaa	142.84	+26.02%	180.01
A Aaaaaa A Aaaa Aaaa	110.17	+21.59%	133.96
Aaaaaaaaa	29.25	+21.44%	35.52
Aaaaaaaaaaaa	27.71	+21.22%	33.59

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Name	Last	Chg. %	Vol.
FSLR	190.69	+22.08%	16.42M
SMCI	38.74	+15.59%	77.71M
PLTR	129.55	+9.36%	126.15M
APP	374.77	+7.72%	7.59M
VST	155.87	+6.69%	6.81M
PSX	126.21	+6.34%	9.04M
NVDA	130.28	+5.92%	273.74M

Name	Last	Chg. %	Vol.
UNH	311.95	-17.64%	48.09M
ELV	376.73	-9.59%	2.55M
HUM	232.04	-8.23%	2.35M
CVS	61.09	-5.74%	13.07M
SPG	161.72	-5.67%	2.57M
CNC	59.58	-5.24%	5.70M
ENPH	45.38	-5.34%	15.02M

Popular Searches

Please try another search

Spyre Therapeutics Inc (SYRE)

SYRE Income Statement

Trending Stocks